<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Psoralen plus ultraviolet A (PUVA) photochemotherapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Psoralen plus ultraviolet A (PUVA) photochemotherapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Psoralen plus ultraviolet A (PUVA) photochemotherapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elisabeth G Richard, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Craig A Elmets, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 01, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H31513778"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Psoralen plus ultraviolet A (PUVA) photochemotherapy combines the administration of psoralens, a class of phototoxic plant-derived compounds, with an exposure to ultraviolet A radiation (UVA). PUVA is used for the treatment of a variety of skin diseases, including psoriasis, mycosis fungoides, eczema, vitiligo, and graft-versus-host disease [<a href="#rid1">1-3</a>].</p><p>This topic will discuss the mechanism of action, treatment protocols, contraindications, adverse effects, and clinical indications of PUVA therapy. The use of PUVA for the treatment of specific skin conditions is discussed separately. UVB phototherapy and UVA1 phototherapy are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Ultraviolet light'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4757.html" rel="external">"Treatment of early stage (IA to IIA) mycosis fungoides", section on 'Phototherapy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/106619.html" rel="external">"Vitiligo: Management and prognosis", section on 'Psoralen plus ultraviolet A photochemotherapy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3550.html" rel="external">"Treatment of chronic graft-versus-host disease", section on 'PUVA (psoralen ultraviolet irradiation)'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13745.html" rel="external">"UVB phototherapy (broadband and narrowband)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/91676.html" rel="external">"UVA1 phototherapy"</a>.)</p><p></p><p class="headingAnchor" id="H31513814"><span class="h1">PSORALENS</span><span class="headingEndMark"> — </span>Psoralens are naturally occurring phototoxic compounds that are able to enter the cell, absorb light photons, and produce a photochemical reaction that alters the function of DNA and other cell constituents. As part of psoralen plus ultraviolet A (PUVA) therapy, psoralens may be applied topically or taken orally.</p><p>Psoralens are produced by a variety of plants of the Apiaceae and Rutaceae families, including fig, lime, celery, and parsnip. The medicinal properties of psoralens have been known for centuries and their use in treating vitiligo was recorded as long ago as 1550 BC [<a href="#rid4">4</a>].</p><p>Three psoralens are used for PUVA therapy (<a class="graphic graphic_table graphicRef83021" href="/d/graphic/83021.html" rel="external">table 1</a>). <a class="drug drug_general" data-topicid="9577" href="/d/drug information/9577.html" rel="external">Methoxsalen</a> or 8-methoxypsoralen (8-MOP) is the most widely used and the only psoralen available in the United States. Trioxsalen or 4,5',8-trimethylpsoralen and bergapten or 5-methoxypsoralen are available in Europe and elsewhere (<a class="graphic graphic_figure graphicRef83609" href="/d/graphic/83609.html" rel="external">figure 1</a>).</p><p class="headingAnchor" id="H3425444"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span>The intestinal absorption rate of psoralens depends upon the physical characteristics of the preparation, concomitant food intake, and individual factors [<a href="#rid5">5-8</a>].</p><p>Variable absorption can impact the effect of psoralen on UVA exposure. Dissolved preparations (eg, soft gelatin capsules) are better absorbed than micronized, crystalline formulations (eg, hard gelatin capsules) and yield peak serum levels in a relatively reproducible time in all subjects (<a class="graphic graphic_table graphicRef83021" href="/d/graphic/83021.html" rel="external">table 1</a>). Food intake retards and decreases the absorption of psoralens. A first-pass effect (eg, the amount of drug that is metabolized by the liver after intestinal absorption, before entering the general circulation) may be the cause of the high interindividual variability in the plasma levels achieved after a fixed dose of <a class="drug drug_general" data-topicid="9577" href="/d/drug information/9577.html" rel="external">methoxsalen</a>.</p><p>In the blood, 75 to 80 percent of <a class="drug drug_general" data-topicid="9577" href="/d/drug information/9577.html" rel="external">methoxsalen</a> is reversibly bound to serum albumin and is distributed to all organs. In the absence of UVA exposure, the binding is short lived and the drug is rapidly metabolized in the liver and excreted with urine as inactive metabolites. Drugs that induce cytochrome P-450 enzymes accelerate the metabolism of methoxsalen and may decrease the biologic effect of PUVA [<a href="#rid7">7,9-11</a>].</p><p>The pharmacokinetics of <a class="drug drug_general" data-topicid="9577" href="/d/drug information/9577.html" rel="external">methoxsalen</a> after transepidermal absorption depends upon the method of application [<a href="#rid12">12</a>]. Methoxsalen 0.15% emulsion or solution applied topically to large body areas leads to plasma levels comparable to those achieved with oral administration. In contrast, plasma levels after whole body bath PUVA treatment are very low. Bathwater-delivered psoralens are readily absorbed in the skin but are promptly eliminated without cutaneous accumulation.</p><p class="headingAnchor" id="H31513821"><span class="h2">Photochemistry</span><span class="headingEndMark"> — </span>Psoralens penetrate into the cells and intercalate between DNA base pairs in the absence of UV exposure. Upon exposure to UVA radiation, the psoralen molecules absorb photons, become chemically activated and covalently bond with DNA base pairs, producing interstrand crosslinks of the double helix (<a class="graphic graphic_figure graphicRef83232" href="/d/graphic/83232.html" rel="external">figure 2</a>).</p><p>DNA crosslinking suppresses DNA synthesis and mitosis and may cause cell apoptosis through the activation of the p53 pathway. Cells with sublethal damage repair the DNA through an error-prone repair process, resulting in mutagenesis and photocarcinogenesis.</p><p>Psoralens also interact with other cell components, including mitochondria, RNA, and proteins. In keratinocyte cultures, psoralens induce mitochondrial depolarization, cytochrome <em>c</em> release, production of reactive oxygen species, and activation of proteases such as caspase-3 and -9 that are implicated in cell apoptosis [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H31513828"><span class="h1">ULTRAVIOLET A SOURCES</span><span class="headingEndMark"> — </span>The wavelengths of ultraviolet A (UVA) lie between 320 and 400 nm in the electromagnetic spectrum (<a class="graphic graphic_figure graphicRef70045" href="/d/graphic/70045.html" rel="external">figure 3</a>). The most common sources of UVA radiation are fluorescent phototherapy light bulbs with maximum emission at 352 nm. UVA doses are measured in joules/cm<sup>2 </sup>(J/cm<sup>2</sup>), most often using a photometer with a maximum sensitivity at 350 to 360 nm. Although in vivo wavelengths most efficient at activating psoralens peak at 320 to 340 nm (UVA2 spectrum (<a class="graphic graphic_figure graphicRef70045" href="/d/graphic/70045.html" rel="external">figure 3</a>)), the longer wavelength emitted by the available lamps is equally effective in clinical practice [<a href="#rid14">14,15</a>]. Psoralen activation also occurs in the UVB spectrum.</p><p>Although a convenient source of UVA, natural sunlight is not safe for use with psoralens because of inherent difficulties in defining the therapeutic dose and increased risk of severe phototoxic reactions [<a href="#rid16">16</a>]. Similarly, the use of tanning beds, which have emission peaks in the range of 320 to 340 nm, may unpredictably activate psoralens with increased risk of severe erythema.</p><p class="headingAnchor" id="H4791974"><span class="h1">MECHANISMS OF ACTION OF PUVA</span><span class="headingEndMark"> — </span>Psoralen plus ultraviolet A (PUVA) exerts its therapeutic effect through multiple mechanisms, some of which are not completely understood. Initially, the mechanism in psoriasis was believed to be the inhibition of keratinocyte proliferation. However, it is now well established that the efficacy of PUVA in the treatment of psoriasis is based upon its immunomodulatory properties. Proposed mechanisms include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhibition of cell proliferation</strong> – The mammalian target of rapamycin (mTOR) signaling, implicated in the regulation of cell growth and proliferation, appears to have a role in the pathogenesis of psoriasis [<a href="#rid17">17</a>]. PUVA may reduce cell proliferation in psoriasis through downregulation of the mTOR signaling pathway [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunosuppression</strong> – The effect of PUVA in inflammatory diseases (with or without a hyperproliferative component) is mediated by its immunomodulatory properties, including alteration of cytokine and cytokine receptor expression, lymphocyte apoptosis, functional perturbation in the types and function of antigen presenting cells, and reduced expression of adhesion molecules [<a href="#rid19">19-23</a>]. The effect of PUVA in the early stages of mycosis fungoides is likely related to the ability of PUVA to induce lymphocyte apoptosis in dermal infiltrates.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Melanogenesis</strong> – PUVA stimulates melanocyte proliferation, melanogenesis, and transfer of melanosomes to keratinocytes [<a href="#rid24">24</a>]. This mechanism of action, while therapeutic in vitiligo, leads to hyperpigmentation as an adverse effect of PUVA in the treatment of other conditions.</p><p></p><p class="headingAnchor" id="H1377222"><span class="h1">PHOTOSENSITIVITY EFFECTS</span><span class="headingEndMark"> — </span>Delayed phototoxic erythema and pigmentation are the main photosensitivity effects of psoralen plus ultraviolet A (PUVA) treatment. The erythema intensity is proportional to the dose of psoralen and ultraviolet A (UVA) radiation, although there is variability in the photosensitivity response among individuals.</p><p>PUVA-induced erythema usually appears 36 to 48 hours after exposure to UVA radiation and peaks at 48 to 96 hours or even up to 120 hours [<a href="#rid25">25</a>]. Erythema occurs in 10 percent of patients. PUVA treatments are usually given 48 hours apart because daily exposure may result in severe delayed cumulative phototoxicity. Excessive doses of PUVA may induce severe erythema with blistering, intense pruritus, or skin pain. (See <a class="local">'Short-term adverse effects'</a> below.)</p><p>PUVA-induced pigmentation may occur in the absence of erythema, particularly with trimethylpsoralen or 5-methoxypsoralen, and is more intense and longer lasting than that produced by sunlight. The efficacy of PUVA is reduced in the presence of intense pigmentation. Therefore, for skin diseases other than vitiligo, higher doses of UVA radiation may be required as treatment proceeds.</p><p class="headingAnchor" id="H31513870"><span class="h1">TREATMENT PROTOCOLS</span><span class="headingEndMark"> — </span>Protocols for psoralen plus ultraviolet A (PUVA) treatment were initially developed for the treatment of psoriasis but may be applied to its use in other conditions.</p><p class="headingAnchor" id="H770375"><span class="h2">Oral PUVA</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9577" href="/d/drug information/9577.html" rel="external">Methoxsalen</a> capsules are taken orally at doses of 0.4 to 0.6 mg/kg actual body weight one to two hours before exposure to ultraviolet A (UVA) radiation (<a class="graphic graphic_table graphicRef83191" href="/d/graphic/83191.html" rel="external">table 2</a>). Soft gelatin formulations of methoxsalen are absorbed faster and provide higher and more reproducible plasma levels than microcrystalline preparations. (See <a class="local">'Pharmacokinetics'</a> above.)</p><p><a class="drug drug_general" data-topicid="9577" href="/d/drug information/9577.html" rel="external">Methoxsalen</a> ideally should be taken with water on an empty stomach, or at least one hour after eating. However, nausea develops in about 30 percent of patients and is more common with soft gelatin preparations because of rapid absorption and increased blood levels. Nausea can be prevented by taking the drug with a small amount of food with high fat content (eg, cheese) or milk.</p><p class="headingAnchor" id="H31513877"><span class="h3">Initial treatment (clearance phase)</span><span class="headingEndMark"> — </span>The initial dose of UVA radiation is based upon one of two factors: the patient's skin type (<a class="graphic graphic_table graphicRef83193 graphicRef60541" href="/d/graphic/83193.html" rel="external">table 3A-B</a>); or the minimal phototoxic dose (MPD) [<a href="#rid12">12,26,27</a>]. The latter is more commonly used in a few specialized centers in Europe.</p><p>The MPD is defined as the minimal dose of UVA that produces a barely perceptible but well-defined erythema when template areas of the skin are exposed to increasing doses of UVA after psoralen ingestion. Erythema readings are performed 48 or 72 hours after testing, at which time the psoralen phototoxicity reaction usually reaches its peak. The MPD test should be performed on previously nonexposed skin (eg, buttocks). Treatment is started using 50 to 70 percent of the MPD.</p><p>Treatments are delivered two or three times per week, at least 48 hours apart. If no erythema is noted, the UVA dose is increased by 0.5 to 1 J/cm<sup>2</sup> in the subsequent treatments until satisfactory control of the disease has been obtained. The dose is then held at that level. If faint erythema is present, the dose of radiation is held constant.</p><p>If skin tenderness or definite erythema is present, treatment is stopped until erythema and pain have diminished. Treatment is then resumed at a lower dose. If localized erythema develops in previously unexposed parts of the body (eg, the breasts or buttocks), shielding may be employed using clothing or sunscreens that protect against UVA radiation and treatment may be continued.</p><p>Repeated exposures are usually required to clear PUVA-responsive diseases, with gradual increment in the UVA dose as pigmentation develops. As an example, improvement of moderate plaque psoriasis is generally noted after 8 to 10 treatments. On average, 25 to 30 treatments are needed for complete clearance [<a href="#rid28">28-32</a>].</p><p>Since arms and legs generally respond to treatment more slowly than the trunk, the extremities may require additional doses of UVA. After the whole body dose, the patient puts on a gown or shorts and t-shirt, and covers his or her head. In patients with skin type I or II, an additional dose of one J/cm<sup>2</sup> is delivered to the limbs and increased by 0.5 J/cm<sup>2</sup> at each subsequent treatment. In patients with skin type ≥III, additional doses of 2 to 4 J/cm<sup>2</sup><strong> </strong>are delivered to the limbs and increased by 0.5 to 1 J/cm<sup>2</sup> at each treatment.</p><p>Adherence to the schedule is critical for treatment success. Decreased frequency of PUVA (eg, once weekly) can result in treatment failure.</p><p class="headingAnchor" id="H31513884"><span class="h3">Maintenance treatment</span><span class="headingEndMark"> — </span>After satisfactory clearing of disease, the final dose of UVA is held constant and the frequency of treatments is gradually reduced to as low as once per month [<a href="#rid32">32</a>]. Ultimately, PUVA therapy can be discontinued for patients in stable remission to avoid overtreatment and the long-term adverse effects of high cumulative doses of PUVA.</p><p>Schedules for maintenance treatment and when to discontinue therapy vary between institutions. The optimal interval between treatments and the duration of the maintenance treatment should be determined for the individual patient, based upon the type of disease and the time to relapse. </p><p class="headingAnchor" id="H31513891"><span class="h3">Treatment of relapses</span><span class="headingEndMark"> — </span>If a significant relapse of the disease occurs after treatment discontinuation or during the maintenance phase, it is appropriate to resume a clearance schedule. For minor recurrences occurring during the maintenance phase, the frequency of treatments may be increased until disease control is achieved.</p><p class="headingAnchor" id="H31513898"><span class="h2">Alternative psoralen administration</span><span class="headingEndMark"> — </span>To avoid the gastrointestinal side effects of oral psoralen, protocols have been developed for psoralen to be applied topically (for localized disease) or by bath immersion.</p><p class="headingAnchor" id="H1941672"><span class="h3">Topical PUVA</span><span class="headingEndMark"> — </span>Topical PUVA may be used as an alternative to oral PUVA in patients with localized diseases, including limited plaque or palmoplantar psoriasis, hand eczema, or localized vitiligo.</p><p>Topical PUVA consists of direct application to the skin of psoralens in creams, ointments, or lotions followed by exposure to UVA radiation. As an example, <a class="drug drug_general" data-topicid="9577" href="/d/drug information/9577.html" rel="external">Methoxsalen</a> 1% lotion can be diluted 1:10 with ethanol to yield a 0.1% solution that is applied to affected skin 15 minutes before exposure to UVA radiation.</p><p>For vitiligo, the initial exposure is 0.5 J/cm<sup>2</sup>. Incremental increases of 0.25 J/cm<sup>2 </sup>are given at each treatment thereafter, until a light pink erythema is achieved in the depigmented skin. UVA dose is either held at this level or adjusted with the goal of maintaining a faint erythema in affected skin until repigmentation occurs. Treatment is given two or three times per week.</p><p>A frequent complication of topical PUVA is an unexpected, usually bullous phototoxic reaction, typically caused by inadvertent exposure to natural sunlight after treatment [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H1376767"><span class="h3">Bath PUVA</span><span class="headingEndMark"> — </span>Bath PUVA consists of whole body immersion or localized skin soaking (eg, of hands or feet) in a 0.5 to 3 mg/L solution of <a class="drug drug_general" data-topicid="9577" href="/d/drug information/9577.html" rel="external">methoxsalen</a> for 15 to 30 minutes. UVA irradiation is performed immediately after, since the photosensitivity decreases rapidly over two hours following immersion.</p><p>The main advantage of bath PUVA is the absence of systemic adverse effects associated with oral psoralens [<a href="#rid34">34</a>]. However, eye protection is still required after bath PUVA since <a class="drug drug_general" data-topicid="9577" href="/d/drug information/9577.html" rel="external">methoxsalen</a> is detectable in the blood after topical application [<a href="#rid35">35</a>].</p><p>Bath PUVA is not widely available and there is no consensus on the optimal treatment protocol [<a href="#rid35">35</a>]. Bath PUVA is not FDA approved. In addition, the long-term adverse effects of bath PUVA, including skin carcinogenesis, are unknown.</p><p class="headingAnchor" id="H31513912"><span class="h1">SAFETY MEASURES</span><span class="headingEndMark"> — </span>It is important to protect skin that is not involved in the disease process from both topical psoralen and ultraviolet A (UVA) exposure during topical psoralen plus ultraviolet A (PUVA). When systemic psoralen is taken, the patient must be protected from additional UV exposure after the treatment. The following measures are recommended:</p><p class="bulletIndent1"><span class="glyph">●</span>In PUVA units, small UV-blocking goggles are used to protect the eyes. If treatment is not required for facial involvement, the face is protected either by use of a broad-spectrum sunscreen with a sun protection factor (SPF) of 50+ or a cloth barrier. Male genitalia are protected with the use of underwear or an athletic supporter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients must protect their eyes after ingesting psoralen (or after bath exposure). Wraparound UV-blocking glasses should be worn when the patient is exposed to sunlight, from the time <a class="drug drug_general" data-topicid="9577" href="/d/drug information/9577.html" rel="external">methoxsalen</a> is ingested until sunset that same day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sun avoidance is advised to minimize pigmentation from natural sunlight. Excessive pigmentation may ultimately limit the effectiveness of PUVA therapy and require higher doses of UVA. The skin should be protected from natural sunlight through appropriate clothing and avoidance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The amount of UVA emitted by common fluorescent lights is insufficient to activate psoralens. Thus, photoprotection is not required in home or office settings.</p><p></p><p class="headingAnchor" id="H1377203"><span class="h1">DRUG INTERACTIONS</span><span class="headingEndMark"> — </span>Phototoxic drugs (eg, thiazides, tetracyclines, fluoroquinolones, phenothiazines, or sulfonamides), and topical preparations (eg, <a class="drug drug_general" data-topicid="8814" href="/d/drug information/8814.html" rel="external">anthralin</a> or <a class="drug drug_general" data-topicid="8878" href="/d/drug information/8878.html" rel="external">coal tar</a>) may augment the action of psoralen plus ultraviolet A (PUVA) and increase the risk of acute phototoxic erythema. (See  <a class="medical medical_review" href="/d/html/6622.html" rel="external">"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment", section on 'Phototoxicity'</a>.)</p><p class="headingAnchor" id="H2099103"><span class="h1">CONTRAINDICATIONS</span><span class="headingEndMark"> — </span>Contraindications to psoralen plus ultraviolet A (PUVA) treatment are listed in the table (<a class="graphic graphic_table graphicRef83207" href="/d/graphic/83207.html" rel="external">table 4</a>). Absolute contraindications include:</p><p class="bulletIndent1"><span class="glyph">●</span>Xeroderma pigmentosa</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy and lactation</p><p class="bulletIndent1"><span class="glyph">●</span>Lupus erythematosus with a history of photosensitivity or a positive Ro antibody</p><p></p><p>PUVA is not contraindicated in patients with cataract or aphakia because most lens implants are UV blocking. The cataracts are protective of the retina. However, patients with cataracts or aphakia should remain particularly vigilant with adequate eye protection measures. (See <a class="local">'Safety measures'</a> above.)</p><p class="headingAnchor" id="H31513947"><span class="h1">ADVERSE EFFECTS</span></p><p class="headingAnchor" id="H31513954"><span class="h2">Short-term adverse effects</span><span class="headingEndMark"> — </span>Short-term adverse effects of psoralen plus ultraviolet A (PUVA) therapy include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nausea</strong> – Nausea is the most common adverse reaction induced by oral PUVA. Taking <a class="drug drug_general" data-topicid="9577" href="/d/drug information/9577.html" rel="external">methoxsalen</a> with a small amount of food with high fat content or milk may prevent or reduce nausea. If nausea persists, the dose of methoxsalen can be decreased by 10 mg. In some patients, antiemetics may be needed. Ginger (ginger ale, ginger snaps) has also been used to reduce the nausea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythema </strong>– Excessive phototoxicity ranging from intense delayed erythema to blistering occurs in about 10 percent of patients during the clearance phase [<a href="#rid36">36</a>]. Treatment is symptomatic and includes cool baths and liberal use of emollients and antipruritics. (See  <a class="medical medical_review" href="/d/html/6624.html" rel="external">"Sunburn", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pruritus and skin pain</strong> – Mild pruritus is common and usually associated with skin dryness. Emollients are generally sufficient to relieve this symptom.</p><p></p><p class="bulletIndent1">Paroxysmal episodes of intense skin pain, described as a deep, burning itch ("PUVA itch" or "PUVA pricks"), with or without erythema, are an uncommon complication of PUVA therapy [<a href="#rid37">37-40</a>]. PUVA itch generally begins on the outer aspect of the arms, thighs, buttocks, and, in females, on the breasts. Episodes can last from seconds and minutes to up to several hours [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1">Pruritus and pain are thought to be caused by phototoxic damage of the dermal nerve endings [<a href="#rid40">40,41</a>]. In severe cases, PUVA should be discontinued until the symptoms resolve (one to three weeks) and resumed using an ultraviolet A (UVA) dose reduced by 10 to 20 percent. There is no definite treatment for PUVA-induced skin pain. <a class="drug drug_general" data-topicid="8840" href="/d/drug information/8840.html" rel="external">Capsaicin</a> 8% cream, urea 4% cream, and oral <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> have been reported as beneficial in a few cases [<a href="#rid37">37,40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subacute phototoxicity</strong> – Subacute phototoxicity manifests as a widespread scaly erythema accompanied by intense pruritus and may occur at any point during treatment, even if the UVA dose has been stable for some time [<a href="#rid36">36</a>]. An important feature is sparing of areas not exposed to UVA light during treatment (eg, axilla and/or inner thigh). Management includes cessation of PUVA therapy, and use of emollients, cool baths, and antipruritic medications until the symptoms subside. PUVA can then be resumed with a UVA dose 30 to 40 percent lower than the last used dose, with gradual increases as tolerated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Excessive pigmentation </strong>–<strong> </strong>Excessive pigmentation is common, especially in patients with skin types ≥III and may decrease the efficacy of treatment [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other adverse effects</strong> – Other short-term adverse effects include reactivation of herpes simplex, bronchoconstriction, drug fever, heart rate increase, photo-onycholysis and melanonychia, friction blisters, and ankle edema [<a href="#rid42">42-44</a>]. Central nervous system disturbances reported with PUVA therapy include headache, dizziness, depression, insomnia, and hyperactivity [<a href="#rid36">36</a>].</p><p></p><p class="headingAnchor" id="H31513961"><span class="h2">Long-term adverse effects</span></p><p class="headingAnchor" id="H31513969"><span class="h3">Photoaging</span><span class="headingEndMark"> — </span>Photoaging occurs in all patients with Fitzpatrick skin types I to IV after long-term PUVA therapy. These changes are partially reversible upon early discontinuation of therapy. Skin types I and II have more marked changes than types III and IV.</p><p>The photoaging changes are similar to those produced by natural sunlight and include hyper- or hypopigmentation, telangiectasia, wrinkles, lentigines, and actinic keratosis. Hypertrichosis has been reported to occur in males and females treated with long-term PUVA [<a href="#rid45">45</a>]. The lentigines seen with long-term PUVA therapy are composed of melanocytes of larger size and with some cellular atypia. Despite the histologic changes, there is no evidence that PUVA lentigines are precursors of melanoma [<a href="#rid46">46-48</a>].</p><p class="headingAnchor" id="H31513976"><span class="h3">Skin cancer</span><span class="headingEndMark"> — </span>Long-term studies have demonstrated a dose-related increase in the incidence of nonmelanoma skin cancers among patients exposed to high cumulative doses of oral PUVA [<a href="#rid49">49-51</a>]. In a 30-year follow-up study of 1330 patients with psoriasis treated with PUVA, the risk of developing one or more squamous or basal cell carcinomas was greatly increased for those exposed to more than 350 treatments (incidence rate ratio 20.9, 95% CI 14.1-31.1) [<a href="#rid51">51</a>]. In patients previously exposed to PUVA, treatment with cyclosporin further increases the risk of developing skin cancer [<a href="#rid52">52</a>].</p><p>Men exposed to PUVA have an increased risk of genital skin cancer. In a cohort of 892 men treated with PUVA, the incidence of invasive scrotal or penile squamous cell carcinoma was 53-fold higher than that expected in the general White population [<a href="#rid53">53</a>].</p><p>Controversy surrounds the issue of long-term PUVA and melanoma. In a 25-year follow-up study, melanoma incidence in patients treated with more than 200 PUVA treatments was eightfold higher than that expected in the general population [<a href="#rid54">54</a>]. In contrast, other data (primarily from Europe) do not show an increased risk of melanoma [<a href="#rid55">55</a>].</p><p>Adding to the controversy, a retrospective study published in 2017 found that psoriasis patients had 1.53 times the risk of developing melanoma and hematologic cancers compared with patients without psoriasis. This risk was not impacted by psoriasis therapies including phototherapy [<a href="#rid56">56</a>]. Prior studies have also identified increased risk of lymphoproliferative cancers and nonmelanoma skin cancers in patients with psoriasis [<a href="#rid57">57</a>].</p><p>Based on these findings, monitoring for skin cancers remains important in patients undergoing phototherapy, including PUVA.</p><p class="headingAnchor" id="H31513983"><span class="h3">Cataracts</span><span class="headingEndMark"> — </span>Long-term PUVA carries a potential risk for cataract formation. However, a 25-year follow-up study did not show an increased risk of visual impairment or cataract formation in patients treated with PUVA [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H31514004"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>Monitoring of patients undergoing psoralen plus ultraviolet A (PUVA) treatment includes [<a href="#rid2">2,59</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin examination</strong> – Complete skin examination for skin cancer, premalignant lesions, and actinic damage is performed before starting treatment and annually thereafter [<a href="#rid59">59</a>]. It is also important to educate patients to recognize the signs of skin cancer and perform skin self-examination.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eye examination</strong> – Eye examination, including slit-lamp exam of lens and cornea and funduscopic examination of the retina, is performed before starting treatment and annually thereafter. (See <a class="local">'Safety measures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory tests</strong> – Laboratory tests are not routinely performed before or during PUVA treatment, unless suggested by history (eg, lupus or photosensitivity).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcome evaluation</strong> – The evaluation of disease activity and treatment efficacy is performed by the treating clinician at three to four month intervals. </p><p></p><p>Ongoing monitoring is indicated in patients who have received prolonged PUVA treatment, since an increased risk of skin cancer may persist after discontinuation of treatment [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H1377419"><span class="h1">CLINICAL INDICATIONS FOR PUVA</span><span class="headingEndMark"> — </span>The potential benefits of psoralen plus ultraviolet A (PUVA) must be weighed against the dose-related risks of long-term therapy in the individual patient. Most common indications for PUVA include moderate to severe psoriasis that is unresponsive to topical therapy and mycosis fungoides. Recognition of the immunosuppressive and antiproliferative effects of PUVA has led to a role for PUVA in the treatment of many other skin diseases, including eczema, vitiligo, and chronic and acute graft-versus-host disease. Additional indications for PUVA therapy are summarized in the table (<a class="graphic graphic_table graphicRef83200" href="/d/graphic/83200.html" rel="external">table 5</a>) [<a href="#rid60">60</a>].</p><p>The use of PUVA for the treatment of specific skin conditions is discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Ultraviolet light'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4757.html" rel="external">"Treatment of early stage (IA to IIA) mycosis fungoides", section on 'Phototherapy'</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/106619.html" rel="external">"Vitiligo: Management and prognosis", section on 'Psoralen plus ultraviolet A photochemotherapy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3550.html" rel="external">"Treatment of chronic graft-versus-host disease", section on 'PUVA (psoralen ultraviolet irradiation)'</a>.)</p><p></p><p class="headingAnchor" id="H31514060"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and indications</strong> – Psoralen plus ultraviolet A (PUVA) photochemotherapy combines the administration of psoralens (<a class="graphic graphic_table graphicRef83021" href="/d/graphic/83021.html" rel="external">table 1</a>) with an exposure to ultraviolet A radiation. PUVA is used for the treatment of a variety of skin diseases, including psoriasis, mycosis fungoides, eczema, vitiligo, and graft-versus-host disease. (See <a class="local">'Introduction'</a> above and <a class="local">'Psoralens'</a> above and <a class="local">'Ultraviolet A sources'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms of action</strong> – The mechanisms of action of PUVA include suppression of DNA synthesis and cell proliferation, lymphocyte apoptosis and perturbation in the type and function of antigen presenting cells, changes in cytokine and cytokine receptor expression, and melanocyte proliferation and increased melanogenesis. (See <a class="local">'Mechanisms of action of PUVA'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effects of PUVA therapy</strong> – The main photosensitivity effects of PUVA include a delayed phototoxic erythema that appears 36 to 48 hours after exposure, and peaks at 48 to 96 hours, and pigmentation. (See <a class="local">'Photosensitivity effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common protocols</strong> – Protocols for PUVA treatment initially developed for the treatment of psoriasis may be applied to the treatment of other conditions. For oral PUVA, which is the most common type of ultraviolet A (UVA) therapy, <a class="drug drug_general" data-topicid="9577" href="/d/drug information/9577.html" rel="external">methoxsalen</a> capsules are taken orally at doses of 0.4 to 0.6 mg/kg one to two hours before exposure to UVA radiation (<a class="graphic graphic_table graphicRef83191" href="/d/graphic/83191.html" rel="external">table 2</a>). (See <a class="local">'Oral PUVA'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Safety measures</strong> – The eyes and the skin that is not involved must be protected during PUVA. Additionally, the eyes must be protected from natural sunlight by wearing UV-blocking sunglasses after ingesting psoralens until sunset that same day. (See <a class="local">'Safety measures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Short term</strong> – Short-term adverse effects of PUVA include nausea, erythema, pruritus, and excessive pigmentation. (See <a class="local">'Short-term adverse effects'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Long term</strong> – Long-term adverse effects of PUVA include photoaging and increased risk of nonmelanoma skin cancer. Skin examination for skin cancer should be performed annually in patients on PUVA therapy. Ongoing monitoring is indicated in patients who have received prolonged PUVA treatment, since an increased risk of skin cancer may persist after discontinuation of treatment. (See <a class="local">'Long-term adverse effects'</a> above.)</p><p></p><p class="headingAnchor" id="H206843443"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Warwick Morison, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Parrish JA, Fitzpatrick TB, Tanenbaum L, Pathak MA. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med 1974; 291:1207.</a></li><li class="breakAll">Morison WL. Phototherapy and Photochemotherapy of Skin Disease, 3rd ed, Taylor and Francis, 2005.</li><li class="breakAll">Abel EA. Photochemotherapy in Dermatology, Igaku-Shoin, 1992.</li><li><a class="nounderline abstract_t">Pathak MA, Fitzpatrick TB. The evolution of photochemotherapy with psoralens and UVA (PUVA): 2000 BC to 1992 AD. J Photochem Photobiol B 1992; 14:3.</a></li><li><a class="nounderline abstract_t">Brickl R, Schmid J, Koss FW. Clinical pharmacology of oral psoralen drugs. Photodermatol 1984; 1:174.</a></li><li><a class="nounderline abstract_t">Roelandts R, Van Boven M, Deheyn T, et al. Dietary influences on 8-MOP plasma levels in PUVA patients with psoriasis. Br J Dermatol 1981; 105:569.</a></li><li><a class="nounderline abstract_t">Herfst MJ, De Wolff FA. Intraindividual and interindividual variability in 8-methoxypsoralen kinetics and effect in psoriatic patients. Clin Pharmacol Ther 1983; 34:117.</a></li><li><a class="nounderline abstract_t">de Wolff FA, Thomas TV. Clinical pharmacokinetics of methoxsalen and other psoralens. Clin Pharmacokinet 1986; 11:62.</a></li><li><a class="nounderline abstract_t">Artuc M, Stuettgen G, Schalla W, et al. Reversible binding of 5- and 8-methoxypsoralen to human serum proteins (albumin) and to epidermis in vitro. Br J Dermatol 1979; 101:669.</a></li><li><a class="nounderline abstract_t">Wulf HC, Andreasen MP. Distribution of 3H-8-MOP and its metabolites in rat organs after a single oral administration. J Invest Dermatol 1981; 76:252.</a></li><li><a class="nounderline abstract_t">Schmid J, Prox A, Reuter A, et al. The metabolism of 8-methoxypsoralen in man. Eur J Drug Metab Pharmacokinet 1980; 5:81.</a></li><li class="breakAll">Honigsmann H, Szemies RM, Knobler R. Photochemotherapy and photodynamic therapy. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al (Eds), McGraw Hill, 2012. Vol 2, p.2851.</li><li><a class="nounderline abstract_t">Viola G, Fortunato E, Cecconet L, et al. Central role of mitochondria and p53 in PUVA-induced apoptosis in human keratinocytes cell line NCTC-2544. Toxicol Appl Pharmacol 2008; 227:84.</a></li><li><a class="nounderline abstract_t">Farr PM, Diffey BL, Higgins EM, Matthews JN. The action spectrum between 320 and 400 nm for clearance of psoriasis by psoralen photochemotherapy. Br J Dermatol 1991; 124:443.</a></li><li><a class="nounderline abstract_t">Cripps DJ, Lowe NJ, Lerner AB. Action spectra of topical psoralens: a re-evaluation. Br J Dermatol 1982; 107:77.</a></li><li><a class="nounderline abstract_t">Parrish JA, White AD, Kingsbury T, et al. Photochemotherapy of psoriasis using methoxsalen and sunlight. A controlled study. Arch Dermatol 1977; 113:1529.</a></li><li><a class="nounderline abstract_t">Buerger C, Malisiewicz B, Eiser A, et al. Mammalian target of rapamycin and its downstream signalling components are activated in psoriatic skin. Br J Dermatol 2013; 169:156.</a></li><li><a class="nounderline abstract_t">Shirsath N, Mayer G, Singh TP, Wolf P. 8-methoxypsoralen plus UVA (PUVA) therapy normalizes signalling of phosphorylated component of mTOR pathway in psoriatic skin of K5.hTGFβ1 transgenic mice. Exp Dermatol 2015; 24:889.</a></li><li><a class="nounderline abstract_t">Sethi G, Sodhi A. Role of p38 mitogen-activated protein kinase and caspases in UV-B-induced apoptosis of murine peritoneal macrophages. Photochem Photobiol 2004; 79:48.</a></li><li><a class="nounderline abstract_t">Laing TJ, Richardson BC, Toth MB, et al. Ultraviolet light and 8-methoxypsoralen inhibit expression of endothelial adhesion molecules. J Rheumatol 1995; 22:2126.</a></li><li><a class="nounderline abstract_t">Singh TP, Schön MP, Wallbrecht K, et al. 8-methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder. J Immunol 2010; 184:7257.</a></li><li><a class="nounderline abstract_t">Johnson R, Staiano-Coico L, Austin L, et al. PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in human T-lymphocytes. Photochem Photobiol 1996; 63:566.</a></li><li><a class="nounderline abstract_t">Liszewski W, Naym DG, Biskup E, Gniadecki R. Psoralen with ultraviolet A-induced apoptosis of cutaneous lymphoma cell lines is augmented by type I interferons via the JAK1-STAT1 pathway. Photodermatol Photoimmunol Photomed 2017; 33:164.</a></li><li><a class="nounderline abstract_t">Mengeaud V, Ortonne JP. PUVA (5-methoxypsoralen plus UVA) enhances melanogenesis and modulates expression of melanogenic proteins in cultured melanocytes. J Invest Dermatol 1996; 107:57.</a></li><li><a class="nounderline abstract_t">Ibbotson SH, Farr PM. The time-course of psoralen ultraviolet A (PUVA) erythema. J Invest Dermatol 1999; 113:346.</a></li><li><a class="nounderline abstract_t">Buckley DA, Phillips WG. 8-Methoxypsoralen PUVA for psoriasis: a comparison of a minimal phototoxic dose-based regimen with a skin-type approach. Br J Dermatol 1997; 136:800.</a></li><li><a class="nounderline abstract_t">Collins P, Wainwright NJ, Amorim I, et al. 8-MOP PUVA for psoriasis: a comparison of a minimal phototoxic dose-based regimen with a skin-type approach. Br J Dermatol 1996; 135:248.</a></li><li class="breakAll">Stern RS, Fitzpatrick TB, Honigsmann H, et al. Psoralen photochemotherapy. In: Psoriasis, Roenigk HH, Maibach HI (Eds), Marcel Dekker, 1985. p.475.</li><li><a class="nounderline abstract_t">Photochemotherapy for psoriasis. A clinical cooperative study of PUVA-48 and PUVA-64. Arch Dermatol 1979; 115:576.</a></li><li><a class="nounderline abstract_t">Henseler T, Wolff K, Hönigsmann H, Christophers E. Oral 8-methoxypsoralen photochemotherapy of psoriasis. The European PUVA study: a cooperative study among 18 European centres. Lancet 1981; 1:853.</a></li><li><a class="nounderline abstract_t">Wolff KW, Fitzpatrick TB, Parrish JA, et al. Photochemotherapy for psoriasis with orally administered methoxsalen. Arch Dermatol 1976; 112:943.</a></li><li><a class="nounderline abstract_t">Melski JW, Tanenbaum L, Parrish JA, et al. Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol 1977; 68:328.</a></li><li><a class="nounderline abstract_t">Gange RW, Levins P, Murray J, et al. Prolonged skin photosensitization induced by methoxsalen and subphototoxic UVA irradiation. J Invest Dermatol 1984; 82:219.</a></li><li><a class="nounderline abstract_t">Halpern SM, Anstey AV, Dawe RS, et al. Guidelines for topical PUVA: a report of a workshop of the British photodermatology group. Br J Dermatol 2000; 142:22.</a></li><li><a class="nounderline abstract_t">Kappes UP, Barta U, Merkel U, et al. High plasma levels of 8-methoxypsoralen following bath water delivery in dermatological patients. Skin Pharmacol Appl Skin Physiol 2003; 16:305.</a></li><li><a class="nounderline abstract_t">Morison WL, Marwaha S, Beck L. PUVA-induced phototoxicity: incidence and causes. J Am Acad Dermatol 1997; 36:183.</a></li><li><a class="nounderline abstract_t">Zamiri M, Bilsland D. Treatment of bath PUVA-induced skin pain with gabapentin. Br J Dermatol 2004; 151:516.</a></li><li><a class="nounderline abstract_t">Tegner E. Severe skin pain after PUVA treatment. Acta Derm Venereol 1979; 59:467.</a></li><li><a class="nounderline abstract_t">Tegner E. Excruciating skin pain after PUVA treatment. Int J Dermatol 1982; 21:207.</a></li><li><a class="nounderline abstract_t">Wyckmans M, Bervoets A. A review on PUVA pricks-A debilitating adverse event. Photodermatol Photoimmunol Photomed 2023; 39:185.</a></li><li><a class="nounderline abstract_t">Kumakiri M, Hashimoto K, Willis I. Biological changes of human cutaneous nerves caused by ultraviolet irradiation: an ultrastructural study. Br J Dermatol 1978; 99:65.</a></li><li><a class="nounderline abstract_t">Prens EP, Smeenk G. Effect of photochemotherapy on the cardiovascular system. Dermatologica 1983; 167:208.</a></li><li><a class="nounderline abstract_t">Mackie RM. Onycholysis occurring during PUVA therapy. Clin Exp Dermatol 1979; 4:111.</a></li><li><a class="nounderline abstract_t">Ledbetter LS, Hsu S. Melanonychia associated with PUVA therapy. J Am Acad Dermatol 2003; 48:S31.</a></li><li><a class="nounderline abstract_t">Rampen FH. Hypertrichosis in PUVA-treated patients. Br J Dermatol 1983; 109:657.</a></li><li><a class="nounderline abstract_t">Gschnait F, Wolff K, Hönigsmann H, et al. Long-term photochemotherapy: histopathological and immunofluorescence observations in 243 patients. Br J Dermatol 1980; 103:11.</a></li><li><a class="nounderline abstract_t">Rhodes AR, Harrist TJ, Momtaz-T K. The PUVA-induced pigmented macule: a lentiginous proliferation of large, sometimes cytologically atypical, melanocytes. J Am Acad Dermatol 1983; 9:47.</a></li><li><a class="nounderline abstract_t">Stern RS. Actinic degeneration and pigmentary change in association with psoralen and UVA treatment: a 20-year prospective study. J Am Acad Dermatol 2003; 48:61.</a></li><li><a class="nounderline abstract_t">Lindelöf B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer: a large-scale epidemiological study. Lancet 1991; 338:91.</a></li><li><a class="nounderline abstract_t">Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol 1998; 134:1582.</a></li><li><a class="nounderline abstract_t">Stern RS, PUVA Follow-Up Study. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol 2012; 66:553.</a></li><li><a class="nounderline abstract_t">Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001; 358:1042.</a></li><li><a class="nounderline abstract_t">Stern RS, Bagheri S, Nichols K, PUVA Follow Up Study. The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis. J Am Acad Dermatol 2002; 47:33.</a></li><li><a class="nounderline abstract_t">Stern RS, Nichols KT, Väkevä LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 1997; 336:1041.</a></li><li><a class="nounderline abstract_t">Morison WL, Baughman RD, Day RM, et al. Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol 1998; 134:595.</a></li><li><a class="nounderline abstract_t">Reddy SP, Martires K, Wu JJ. The risk of melanoma and hematologic cancers in patients with psoriasis. J Am Acad Dermatol 2017; 76:639.</a></li><li><a class="nounderline abstract_t">Margolis D, Bilker W, Hennessy S, et al. The risk of malignancy associated with psoriasis. Arch Dermatol 2001; 137:778.</a></li><li><a class="nounderline abstract_t">Malanos D, Stern RS. Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study. J Am Acad Dermatol 2007; 57:231.</a></li><li><a class="nounderline abstract_t">Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010; 62:114.</a></li><li class="breakAll">Morison WL, Richard EG. PUVA photochemotherapy and other phototherapy modalities. In: Comprehensive Dermatologic Drug Therapy, 3rd ed, Wolverton SE (Ed), Saunders Elsevier, 2013.</li></ol></div><div id="topicVersionRevision">Topic 13749 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4422691" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4422691" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4422691" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1432383" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The evolution of photochemotherapy with psoralens and UVA (PUVA): 2000 BC to 1992 AD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6397736" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical pharmacology of oral psoralen drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7295571" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Dietary influences on 8-MOP plasma levels in PUVA patients with psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6861433" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Intraindividual and interindividual variability in 8-methoxypsoralen kinetics and effect in psoriatic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3512141" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical pharmacokinetics of methoxsalen and other psoralens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/534612" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Reversible binding of 5- and 8-methoxypsoralen to human serum proteins (albumin) and to epidermis in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7205026" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Distribution of 3H-8-MOP and its metabolites in rat organs after a single oral administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7398681" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The metabolism of 8-methoxypsoralen in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7398681" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The metabolism of 8-methoxypsoralen in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18048073" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Central role of mitochondria and p53 in PUVA-induced apoptosis in human keratinocytes cell line NCTC-2544.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2039720" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The action spectrum between 320 and 400 nm for clearance of psoriasis by psoralen photochemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7104210" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Action spectra of topical psoralens: a re-evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/337903" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Photochemotherapy of psoriasis using methoxsalen and sunlight. A controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23398394" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mammalian target of rapamycin and its downstream signalling components are activated in psoriatic skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26121067" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : 8-methoxypsoralen plus UVA (PUVA) therapy normalizes signalling of phosphorylated component of mTOR pathway in psoriatic skin of K5.hTGFβ1 transgenic mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14974715" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Role of p38 mitogen-activated protein kinase and caspases in UV-B-induced apoptosis of murine peritoneal macrophages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8596155" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Ultraviolet light and 8-methoxypsoralen inhibit expression of endothelial adhesion molecules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20488788" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : 8-methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8628746" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in human T-lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28196286" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Psoralen with ultraviolet A-induced apoptosis of cutaneous lymphoma cell lines is augmented by type I interferons via the JAK1-STAT1 pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8752840" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : PUVA (5-methoxypsoralen plus UVA) enhances melanogenesis and modulates expression of melanogenic proteins in cultured melanocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10469332" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The time-course of psoralen ultraviolet A (PUVA) erythema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9205529" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : 8-Methoxypsoralen PUVA for psoriasis: a comparison of a minimal phototoxic dose-based regimen with a skin-type approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8881668" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : 8-MOP PUVA for psoriasis: a comparison of a minimal phototoxic dose-based regimen with a skin-type approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8881668" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : 8-MOP PUVA for psoriasis: a comparison of a minimal phototoxic dose-based regimen with a skin-type approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/375839" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Photochemotherapy for psoriasis. A clinical cooperative study of PUVA-48 and PUVA-64.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6112291" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Oral 8-methoxypsoralen photochemotherapy of psoriasis. The European PUVA study: a cooperative study among 18 European centres.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/820269" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Photochemotherapy for psoriasis with orally administered methoxsalen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/864273" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6699425" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prolonged skin photosensitization induced by methoxsalen and subphototoxic UVA irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10651690" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Guidelines for topical PUVA: a report of a workshop of the British photodermatology group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12907835" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : High plasma levels of 8-methoxypsoralen following bath water delivery in dermatological patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9039165" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : PUVA-induced phototoxicity: incidence and causes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15327572" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Treatment of bath PUVA-induced skin pain with gabapentin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/93376" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Severe skin pain after PUVA treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7095947" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Excruciating skin pain after PUVA treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35906863" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A review on PUVA pricks-A debilitating adverse event.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/678467" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Biological changes of human cutaneous nerves caused by ultraviolet irradiation: an ultrastructural study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6642037" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effect of photochemotherapy on the cardiovascular system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/445871" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Onycholysis occurring during PUVA therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12582381" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Melanonychia associated with PUVA therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6652041" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Hypertrichosis in PUVA-treated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7000141" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Long-term photochemotherapy: histopathological and immunofluorescence observations in 243 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6411778" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The PUVA-induced pigmented macule: a lentiginous proliferation of large, sometimes cytologically atypical, melanocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12522372" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Actinic degeneration and pigmentary change in association with psoralen and UVA treatment: a 20-year prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1676477" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : PUVA and cancer: a large-scale epidemiological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9875197" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22264671" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11589933" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12077578" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9091799" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9606329" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Consensus workshop on the toxic effects of long-term PUVA therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27876302" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The risk of melanoma and hematologic cancers in patients with psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11405770" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The risk of malignancy associated with psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17532094" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19811850" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
